Implantation of the clinical‐grade human neural stem cell line, CTX0E03, rescues the behavioral and pathological deficits in the quinolinic acid‐lesioned rodent model of Huntington's disease
Yoon Y, Kim HS, Jeon I, Noh J, Park HJ, Lee S, Park I, Stevanato L, Hicks C, Corteling R, Barker RA, Sinden JD, Song J. Implantation of the clinical‐grade human neural stem cell line, CTX0E03, rescues the behavioral and pathological deficits in the quinolinic acid‐lesioned rodent model of Huntington's disease. Stem Cells 2020, 38: 936-947. PMID: 32374064, PMCID: PMC7496241, DOI: 10.1002/stem.3191.Peer-Reviewed Original ResearchConceptsMedium spiny neuronsNeural stem cell lineHuntington's diseaseQuinolinic acid (QA) lesion rat modelChronic ischemic stroke patientsStriatal medium spiny neuronsCell linesImmortalized neural stem cell linesIschemic stroke patientsDisease-modifying therapiesSignals of efficacyGlial scar formationHost brain tissueHuman neural stem cell lineSignificant behavioral improvementAutosomal dominant neurodegenerative diseaseCTX0E03 cellsEndogenous neurogenesisBDNF expressionGABAergic neuronsHD patientsStroke patientsFluoro-GoldRetrograde labelSpiny neurons